ZME Science on MSN11h
Could CAR-T Therapy Be the End of Lifelong Lupus Medication? Early Results Say ‘Yes’T-cells are real life saviors. If modified properly, they can save lupus patients from the trouble of taking medicines ...
Glioblastoma (GBM) is the most common kind of malignant brain tumor in adults. In recent years, the tumor microenvironment ...
Researchers advance CAR T cell therapy for solid tumors by innovating ways to overcome the unique barriers of solid tumor ...
AZoLifeSciences on MSN1d
A Closer Look at CAR T-Cell Therapy — Successes, Challenges, And FutureT-cell therapy is a revolutionary immunotherapy approach in which T cells are genetically modified to express a receptor that ...
These findings suggest that KIR2DS2-positive (KIR2DS2+) natural killer (NK) cells could be an attractive therapeutic target ...
MedPage Today on MSN7d
Overcoming the Challenges of Applying CAR T-Cell Therapy to Solid TumorsOpens in a new tab or window Share on X. Opens in a new tab or window Share on LinkedIn. Opens in a new tab or window ...
Marker Therapeutics was awarded a $2 million grant from NIH Small Business Innovation Research Program (SBIR) to support the clinical investigation of MT-601 in patients with lymphoma who have ...
A recent meta-analysis investigating cardiovascular complications in adults undergoing chimeric antigen receptor (CAR) T-cell ...
INT2104 is a novel in vivo chimeric antigen receptor (CAR) gene therapy designed to generate CAR-T and CAR-NK cells in the patient’s body to target CD20-expressing malignant B cells Interim ...
PHILADELPHIA, Oct. 23, 2024 (GLOBE NEWSWIRE) -- Interius BioTherapeutics, a clinical-stage company engineering targeted, programmable vectors for the precision delivery of genetic medicines, today ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback